Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 15, 2019

SELL
$3.1 - $4.54 $681,916 - $998,677
-219,973 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$2.65 - $9.2 $582,928 - $2.02 Million
219,973 New
219,973 $640,000

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $116M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track G2 Investment Partners Management LLC Portfolio

Follow G2 Investment Partners Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of G2 Investment Partners Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on G2 Investment Partners Management LLC with notifications on news.